Table 6.
Generic medicinal products submitted with studies having four dosing periods.
| Procedure number | Product name | Study | Finalised regulatory evaluation (Year) |
|---|---|---|---|
| EMEA/H/C/002362 | CAPECITABINE TEVA | 130/09-06.CE and 005/10-06.CE | 2012 |
| EMEA/H/C/002050/0000 | CAPECITABINE SUN | CPB 500T IR 3265 11(a) | 2013 |
| EMEA/H/C/001226 | CLOPIDOGREL TEVA PHARMA B.V. | 2009-2089 | 2011 |
| EMEA/H/C/002025 | IASIBON | IAT-P9-457 | 2010 |
| EMEA/H/C/001195 | IBANDRONIC ACID TEVA | IAT-P7-289 | 2010 |
| EMEA/H/C/1218 | MYCLAUSEN | Study 3668 | 2010 |
| EMEA/H/C/002676/0000 | ACTELSAR HCT | 2335/11 | 2013 |